Home › Trials › NCT07677787
Clinical trial Recruiting at 1 site Interventional Ages 18 to 80

DLL3-targeted PET/CT for small cell lung cancer

Official title: Delta-like Protein 3 (DLL3)- Targeted PET Imaging in Small Cell Lung Cancer

Run by The First Affiliated Hospital of Xiamen University · NCT07677787 · Data updated 2026-11-12

This study tests whether DLL3-targeted PET/CT can better detect lesions in people with suspected or confirmed small cell lung cancer compared with standard imaging.

Quick facts

Study typeInterventional
Ages18 Years to 80 Years
SexAll
Enrollment20 (estimated)
SponsorThe First Affiliated Hospital of Xiamen University
Academic / other
Locations1 site (Xiamen, Fujian)
StatusRecruiting
StartedMay 9, 2026
Main results expectedMay 31, 2028
Study endsMay 31, 2028
Registry record updatedJuly 1, 2026
Trial IDNCT07677787 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with suspected, newly diagnosed, or previously treated small cell lung cancer, evidence of DLL3 expression risk factors, adequate organ function, and ability to provide informed consent.

Probably not a fit

Patients whose tumors do not express DLL3 or whose disease is not detectable by DLL3-targeted PET/CT may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial compares DLL3-targeted PET/CT with conventional imaging (CT, MRI or 18F-FDG PET/CT) in patients with suspected, newly diagnosed, or recurrent small cell lung cancer. It measures tumor uptake using SUVmax and correlates imaging results with tumor DLL3 expression to assess feasibility and diagnostic accuracy. Participants undergo both DLL3-targeted PET/CT and standard imaging during initial assessment or for monitoring metastases or recurrence. Diagnostic performance of the DLL3-targeted approach is evaluated against conventional imaging. The study is conducted at a single center in Xiamen, China, with adults 18 years and older who meet specific biomarker and consent criteria.

Why it matters

Potential benefit: If successful, DLL3-targeted PET/CT could improve lesion detection and staging in SCLC, potentially guiding treatment decisions.

How similar studies have gone: Prior work in targeted PET imaging for cancer has shown feasibility, but DLL3-targeted imaging in SCLC is an emerging approach without wide validation.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Adult patients (aged 18 years or older);
* Patients with suspected, newly diagnosed, and previously treated small cell lung cancer(supporting evidence may include imaging findings and pathology report);
* Serum ProGRP or NSE level ≥ 3 times the upper limit of normal;
* Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
* Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;

Exclusion Criteria:

* The inability or unwillingness of the research participant or legal representative to provide written informed consent.
* Inability to complete PET/CT imaging.

Where it's running

  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
PET/CT 43Small Cell Lung Cancer ( SCLC ) 38The First Affiliated Hospital of Xiamen University 58
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.